Altimmune (ALT) Non-Current Deffered Revenue (2010 - 2018)

Altimmune (ALT) has 5 years of Non-Current Deffered Revenue data on file, last reported at $1.0 million in Q4 2018.

• Non-Current Deffered Revenue for Q4 2018 came in at $1.0 million, up 170.59% year-over-year; the trailing twelve-month figure through Dec 2018 was $1.0 million (up 170.59% YoY), and the FY2018 annual result was $1.0 million, up 170.59% from the prior year.
• Non-Current Deffered Revenue rose to $1.0 million in Q4 2018 per ALT's latest filing, from $144838.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $1.1 million in Q1 2018 and troughed at $1591.0 in Q3 2017.
• A 3-year average of $379016.9 and a median of $164604.5 in 2016 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2017 and 2018: Non-Current Deffered Revenue jumped 115.41% in 2017, then jumped 9003.58% in 2018.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $179424.0 in 2016, then jumped by 115.41% to $386489.0 in 2017, then surged by 170.59% to $1.0 million in 2018.
• Business Quant data shows ALT's Non-Current Deffered Revenue at $1.0 million in Q4 2018, $144838.0 in Q3 2018, and $149785.0 in Q2 2018.